Table 4.
Univariate and Multivariate Survival Analysis
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| P-value | HR (95% CI) | P-value | HR (95% CI) | |
| Clinical stage | ||||
| T1-T2a | - | 1.0 (reference) | - | - |
| T2b-c | 0.162 | 2.51 (0.69–9.16) | - | - |
| T3a | 0.227 | 2.23 (0.6–8.28) | - | - |
| T3b-T4 | 0.045 | 3.91 (1.02–14.86) | 0.138 | 1.33 (0.91–1.93) |
| Gleason score | ||||
| ≤ 6 | - | 1.0 (reference) | - | - |
| 7 | 0.223 | 3.65 (0.45–29.42) | - | - |
| 8–10 | 0.34 | 2.66 (0.35–19.87) | - | - |
| PSA | ||||
| <40 | - | 1.0 (reference) | - | - |
| ≥40 | <0.001 | 3.84 (1.82–8.080 | 0.001 | 3.75 (1.76–7.97) |
| >4 cores positive with Gleason 8–10 | ||||
| ≤4 | - | 1.0 (reference) | - | - |
| >4 | 0.032 | 2.27 (1.07–4.8) | 0.23 | 1.41 (0.8–2.51) |
| Unknown | 0.635 | 0.6 (0.07–4.7) | - | - |
| Primary Gleason pattern | ||||
| <5 | - | 1.0 (reference) | - | - |
| 5 | 0.124 | 2.12 (0.81–5.55) | - | - |
| NCCN risk | ||||
| High risk | - | 1.0 (reference) | - | - |
| VHR | 0.07 | 1.99 (0.94–4.23) | - | - |
| RT technique | ||||
| 3D | - | 1.0 (reference) | - | - |
| IMRT | 0.392 | 1.57 (0.55–4.41) | - | - |
| VMAT | 0.376 | 1.67 (0.53–5.22) | - | - |